Anebulo Pharmaceuticals (ANEB) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Anebulo Pharmaceuticals (NASDAQ: ANEB) is set to release its Q4 2025 earnings on September 24th, with expectations of a loss of ($0.05) per share.
• The company's stock opened at $2.49 and has a market capitalization of approximately $102.29 million, with a 12-month price range between $0.80 and $3.42.
• Following a report on July 23rd, Maxim Group downgraded Anebulo from a "strong-buy" to a "hold" rating, with the stock currently having an average price target of $5.50.

Anebulo Pharmaceuticals (NASDAQ:ANEB - Get Free Report) is projected to post its Q4 2025 results before the market opens on Wednesday, September 24th. Analysts expect Anebulo Pharmaceuticals to post earnings of ($0.05) per share for the quarter. Individuals can check the company's upcoming Q4 2025 earningsummary page for the latest details on the call scheduled for Monday, September 22, 2025 at 4:00 PM ET.

Anebulo Pharmaceuticals Price Performance

Anebulo Pharmaceuticals stock opened at $2.49 on Wednesday. The stock has a market capitalization of $102.29 million, a PE ratio of -9.58 and a beta of -0.89. Anebulo Pharmaceuticals has a 12 month low of $0.80 and a 12 month high of $3.42. The business has a 50 day simple moving average of $2.40 and a 200-day simple moving average of $1.64.

Analysts Set New Price Targets

Separately, Maxim Group cut Anebulo Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $5.50.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. purchased a new position in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 47,954 shares of the company's stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned about 0.12% of Anebulo Pharmaceuticals at the end of the most recent quarter. 28.40% of the stock is currently owned by hedge funds and other institutional investors.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.